Are Hiccups a Side Effect of Mounjaro? Exploring the Connection

Last reviewed: July 12, 2026

Last updated: July 12, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, the active ingredient in Mounjaro, works by activating GLP-1 and GIP receptors to regulate appetite and blood sugar. While nausea, vomiting, and constipation appear frequently in clinical data, hiccups are rarely documented as a direct medication side effect—though some patients describe unusual sensations as their body adjusts to hormonal changes.

Is Hiccups a Known Tirzepatide Side Effect?

Clinical trials of tirzepatide did not identify hiccups as a significant or common adverse event. The most frequently reported gastrointestinal side effects include nausea (25–38% of participants), vomiting (7–15%), constipation (20–25%), and diarrhea (10–20%). Hiccups—involuntary contractions of the diaphragm muscle—were not highlighted in phase 3 trial safety summaries or FDA labeling documentation.

However, individual case reports and patient forums occasionally mention hiccups occurring during the first few weeks of tirzepatide treatment. These anecdotal reports may reflect the medication's broader effects on digestive muscle tone, nutrient absorption patterns, or stomach distension rather than a direct pharmacological action. The rarity of these reports suggests hiccups, if they occur, are likely temporary and related to adjustment rather than a predictable drug effect.

How GLP-1 and GIP Activation May Trigger Muscle Changes

Tirzepatide activates two hormone pathways: GLP-1 receptors slow stomach emptying and increase satiety signals, while GIP receptors modulate glucose metabolism and may influence muscle coordination. Together, these pathways alter the rate and rhythm at which food moves through the digestive tract, which can indirectly affect nearby muscles including the diaphragm. Some patients transitioning to slower digestion may experience transient muscle contractions as their gastrointestinal system recalibrates.

The diaphragm sits directly beneath the lungs and controls breathing. When the stomach, esophagus, or surrounding tissues change in tone or distension due to medication effects, the phrenic nerve—which controls the diaphragm—may receive altered signals. This theoretical connection explains why some patients report hiccups or other breathing-adjacent sensations early in treatment, though these effects typically resolve within days to weeks as the body adapts.

What Clinical Data Shows About Tirzepatide's Actual Side Effect Profile

Phase 3 trials enrolled over 2,400 participants across multiple studies comparing tirzepatide to placebo and insulin degludec. Gastrointestinal events dominated the adverse event list: nausea peaked in weeks 2–4, constipation developed later as dosing increased, and diarrhea occurred in a smaller subset. Serious adverse events (hospitalization-level) were rare and not clearly tied to the medication itself. No pattern of diaphragm-related or hiccup-related events emerged across thousands of patient-months of exposure.

Real-world data from over 1 million patients using tirzepatide since 2023 has not flagged hiccups as a reportable safety signal. Regulatory agencies and compounding pharmacies continue to monitor side effect frequencies, and hiccups remain absent from updated safety communications. This absence of signal—even with massive population exposure—strongly suggests that if hiccups do occur in a tirzepatide user, the connection is coincidental or related to individual factors rather than a class or compound effect.

What to Do If You Experience Hiccups While Taking Tirzepatide

If you develop hiccups after starting tirzepatide, the first step is to confirm timing: did they begin within the first week or two of treatment, or did they appear after a dose increase? Early hiccups (week 1–3) are more likely related to gastrointestinal adjustment and typically stop on their own. Later-onset or persistent hiccups may reflect an unrelated medical condition (gastroesophageal reflux, irritation from rapid eating, or neurological causes) that coincidentally occurred during treatment.

PlexusDx recommends logging when hiccups occur, how long they last, and whether they follow a pattern. This information helps your healthcare provider distinguish treatment-related effects from pre-existing conditions. If hiccups persist beyond 2 weeks, worsen with dose increases, or occur alongside severe nausea or vomiting, contact your prescribing clinician. In most cases, simple adjustments—eating smaller meals, staying hydrated, or slowing your injection schedule—resolve the issue without stopping medication. Your dose may need to go up. Your price won't—PlexusDx maintains flat monthly pricing at $289 for compounded tirzepatide injection regardless of dose level, removing financial barriers to finding your optimal dose.

How Genetic Personalization Can Reduce Unwanted Effects

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

By identifying your genetic peptide profile before or during your first month of treatment, PlexusDx clinicians can personalize your tirzepatide dose trajectory to minimize early gastrointestinal disruption—including any transient muscle or breathing-related sensations. This precision approach reduces the trial-and-error phase, lowers the chance of stopping treatment due to side effects, and accelerates your path to therapeutic dosing. The Precision Peptide Genetic Test costs $99 as an add-on after your first month of medication, and results inform long-term treatment optimization.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Did hiccups appear in Mounjaro clinical trials as a side effect?

No. Hiccups were not identified as a common or significant adverse event in phase 3 tirzepatide trials. Gastrointestinal effects like nausea, constipation, and vomiting were documented, but hiccups did not emerge as a recognized pattern.

Why might someone on tirzepatide experience hiccups if it's not listed as a side effect?

Tirzepatide slows stomach emptying and alters digestive muscle tone through GLP-1 and GIP receptor activation. These changes can indirectly affect the diaphragm and nearby muscles during the first few weeks as your body adjusts. Most hiccups in this context resolve quickly without intervention.

How long do tirzepatide-related hiccups typically last?

If hiccups are adjustment-related, they usually resolve within days to a few weeks as your gastrointestinal system stabilizes. Persistent hiccups beyond 2–3 weeks are more likely due to an unrelated cause and warrant evaluation by your healthcare provider.

Can PlexusDx help me avoid hiccups or other side effects with tirzepatide?

PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after month one) to identify your unique GLP1R, GIPR, FTO, and MC4R variants. This insight allows your clinician to personalize your dose trajectory, reducing early gastrointestinal disruption and improving treatment tolerance. Compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) with flat pricing regardless of dose level.

What should I do if hiccups persist while taking compounded tirzepatide from PlexusDx?

Contact your PlexusDx-affiliated prescriber with a detailed report of when hiccups started and whether they align with dose increases. Your clinician may recommend slower titration, smaller meals, or evaluation for unrelated causes. Most cases resolve without stopping treatment, and genetic testing can guide your personalized dose adjustment strategy.

Related Reading

• Mounjaro Side Effects Plexusdx
• Mounjaro Side Effects
• Hers Mounjaro
• Hims Mounjaro

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.